MARKET

IXHL

IXHL

Incannex Healthcare Ltd
NASDAQ
2.280
-0.070
-2.98%
Closed 16:08 04/23 EDT
OPEN
2.320
PREV CLOSE
2.350
HIGH
2.360
LOW
2.250
VOLUME
8.85K
TURNOVER
0
52 WEEK HIGH
12.68
52 WEEK LOW
0.8000
MARKET CAP
36.19M
P/E (TTM)
-6.0638
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IXHL last week (0415-0419)?
Weekly Report · 2d ago
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 6d ago
INCANNEX HEALTHCARE INC: INTENDS TO SUBMIT NDA FOR IHL-42X FIXED DOSE COMBINATION DRUG TO FDA USING 505(B)2 PATHWAY
Reuters · 04/16 12:10
Weekly Report: what happened at IXHL last week (0408-0412)?
Weekly Report · 04/15 09:56
Weekly Report: what happened at IXHL last week (0401-0405)?
Weekly Report · 04/08 09:58
Weekly Report: what happened at IXHL last week (0325-0329)?
Weekly Report · 04/01 09:57
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Weekly Report: what happened at IXHL last week (0318-0322)?
Weekly Report · 03/25 09:59
More
About IXHL
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

Webull offers Incannex Healthcare Inc stock information, including NASDAQ: IXHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IXHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IXHL stock methods without spending real money on the virtual paper trading platform.